Thrombin-activatable fibrinolysis inhibitor polymorphisms and recurrent pregnancy loss

Fertility and Sterility

Volumn 92, Issue 2, 2009, Pages 694-702

  Masini, Silvia ^a   Ticconi, Carlo ^a   Gravina, Paolo ^a   Tomassini, Monica ^a   Pietropolli, Adalgisa ^a   Forte, Vittorio ^a   Federici, Giorgio ^a,b   Piccione, Emilio ^a   Bernardini, Sergio ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

genetic polymorphisms; recurrent pregnancy loss; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREGNANCY DISORDER; PRIORITY JOURNAL; RECURRENT DISEASE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SPONTANEOUS ABORTION;

ABORTION, HABITUAL; ADULT; CARBOXYPEPTIDASE U; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; ITALY; POLYMORPHISM, SINGLE NUCLEOTIDE; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 67649143244     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2008.07.015     Document Type: Article

References (49)

1. Patnaik M.M., Haddad T., and Morton C.T. Pregnancy and thrombophilia. Expert Rev Cardiovasc Ther 5 (2007) 753-765
2. Blumenfeld Z., and Brenner B. Thrombophilia-associated pregnancy wastage. Fertil Steril 72 (1999) 765-774
3. Sotiriadis A., Makrigiannakis A., Stefos T., Paraskevaidis E., and Kalantaridou S.N. Fibrinolytic defects and recurrent miscarriage: a systematic review and meta-analysis. Obstet Gynecol 109 (2007) 1146-1155
4. Lindoff C., Lecander I., and Astedt B. Fibrinolytic components in individual consecutive plasma samples during normal pregnancy. Fibrinolysis 7 (1993) 190-194
5. Bouma B.N., and Mosnier L.O. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol Haemost Thromb 33 (2003) 375-381
6. Bajzar L., Manuel R., and Nesheim M.E. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 270 (1995) 14477-14484
7. Eaton D.L., Malloy B.E., Tsai S.P., Henzel W., and Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 266 (1991) 21833-21838
8. Mosnier L.O., and Bouma B.N. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol 26 (2006) 2445-2453
9. Mosnier L.O., Buijtenhuijs P., Marx P.F., Meijers J.C., and Bouma B.N. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 101 (2003) 4844-4846
10. Bajzar L., Morser J., and Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 271 (1996) 16603-16608
11. Wang W., Boffa M.B., Bajzar L., Walker J.B., and Nesheim M.E. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem 273 (1998) 27176-27181
12. Myles T., Nishimura T., Yun T.H., Nagashima M., Morser J., Patterson A.J., et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 278 (2003) 51059-51067
13. Mosnier L.O., von dem Borne P.A., Meijers J.C., and Bouma B.N. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 80 (1998) 829-835
14. Boffa M.B., and Koschinsky M.L. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem 40 (2007) 431-442
15. Henry M., Aubert H., Morange P.E., Nanni I., Alessi M.C., Tiret L., et al. Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 97 (2001) 2053-2058
16. Vanhoof G., Wauters J., Schatteman K., Hendriks D., Goossens F., Bossuyt P., et al. The gene for human carboxypeptidase U (CPU)-a proposed novel regulator of plasminogen activation-maps to 13q14.11. Genomics 38 (1996) 454-455
17. Boffa M.B., Reid T.S., Joo E., Nesheim M.E., and Koschinsky M.L. Characterization of the gene encoding human TAFI (thrombin-activatable fibrinolysis inhibitor; plasma procarboxypeptidase B). Biochemistry 38 (1999) 6547-6558
18. Frere C., Morange P.E., Saut N., Tregouet D.A., Grosley M., Beltran J., et al. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. Thromb Haemost 94 (2005) 373-379
19. Franco R.F., Fagundes M.G., Meijers J.C., Reitsma P.H., Lourenco D., Morelli V., et al. Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 86 (2001) 510-517
20. Santamaria A., Oliver A., Borrell M., Mateo J., Belvis R., Marti-Fabregas J., et al. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke 34 (2003) 2387-2391
21. Silveira A., Schatteman K., Goossens F., Moor E., Scharpe S., Stromqvist M., et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 84 (2000) 364-368
22. Juhan-Vague I., Renucci J.F., Grimaux M., Morange P.E., Gouvernet J., Gourmelin Y., et al. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 20 (2000) 2156-2161
23. Willemse J.L., and Hendriks D.F. A role for procarboxypepidase U (TAFI) in thrombosis. Front Biosci 12 (2007) 1973-1987
24. Eichinger S., Schonauer V., Weltermann A., Minar E., Bialonczyk C., Hirschl M., et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 103 (2004) 3773-3776
25. van Tilburg N.H., Rosendaal F.R., and Bertina R.M. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95 (2000) 2855-2859
26. Chabloz P., Reber G., Boehlen F., Hohlfeld P., and de Moerloose P. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br J Haematol 115 (2001) 150-152
27. Goodman C.S., Coulam C.B., Jeyendran R.S., Acosta V.A., and Roussev R. Which thrombophilic gene mutations are risk factors for recurrent pregnancy loss?. Am J Reprod Immunol 56 (2006) 230-236
28. Christiansen O.B., Nybo Andersen A.M., Bosch E., Daya S., Delves P.J., Hviid T.V., et al. Evidence-based investigations and treatments of recurrent pregnancy loss. Fertil Steril 83 (2005) 821-839
29. Lala P.K., and Chakraborty C. Factors regulating trophoblast migration and invasiveness: possible derangements contributing to pre-eclampsia and fetal injury. Placenta 24 (2003) 575-587
30. Boffa M.B., Maret D., Hamill J.D., Bastajian N., Crainich P., Jenny N.S., et al. Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin activatable fibrinolysis inhibitor: a functional analysis. Blood 12 (2007) 12
31. Rai R., and Regan L. Recurrent miscarriage. Lancet 368 (2006) 601-611
32. Falconer H., D'Hooghe T., and Fried G. Endometriosis and genetic polymorphisms. Obstet Gynecol Surv 62 (2007) 616-628
33. Leebeek F.W., Goor M.P., Guimaraes A.H., Brouwers G.J., Maat M.P., Dippel D.W., et al. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 3 (2005) 2211-2218
34. Montaner J., Ribo M., Monasterio J., Molina C.A., and Alvarez-Sabin J. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 34 (2003) 1038-1040
35. Juhan-Vague I., Morange P.E., Aubert H., Henry M., Aillaud M.F., Alessi M.C., et al. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 22 (2002) 867-873
36. Brouwers G.J., Leebeek F.W., Tanck M.W., Wouter Jukema J., Kluft C., and de Maat M.P. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Thromb Haemost 90 (2003) 92-100
37. Martini C.H., Brandts A., de Bruijne E.L., van Hylckama Vlieg A., Leebeek F.W., Lisman T., et al. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. Br J Haematol 134 (2006) 92-94
38. Kjellberg U., Andersson N.E., Rosen S., Tengborn L., and Hellgren M. APC resistance and other haemostatic variables during pregnancy and puerperium. Thromb Haemost 81 (1999) 527-531
39. Wright J.G., Cooper P., Astedt B., Lecander I., Wilde J.T., Preston F.E., et al. Fibrinolysis during normal human pregnancy: complex inter-relationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time. Br J Haematol 69 (1988) 253-258
40. Marchi R., Lopez Ramirez Y., Nagaswami C., Masova L., Pulido A., Lopez Mora J., et al. Haemostatic changes related to fibrin formation and fibrinolysis during the first trimester in normal pregnancy and in recurrent miscarriage. Thromb Haemost 97 (2007) 552-557
41. Mousa H.A., Downey C., Alfirevic Z., and Toh C.H. Thrombin activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy. Thromb Haemost 92 (2004) 1025-1031
42. Watanabe T., Minakami H., Sakata Y., Matsubara S., Sato I., and Suzuki M. Changes in activity of plasma thrombin activatable fibrinolysis inhibitor in pregnancy. Gynecol Obstet Invest 58 (2004) 19-21
43. Chetaille P., Alessi M.C., Kouassi D., Morange P.E., and Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 83 (2000) 902-905
44. Uszynski W., Uszynski M., Zekanowska E., and Goralczyk K. Thrombin activatable fibrinolysis inhibitor (TAFI) in cord blood. Folia Histochem Cytobiol 45 (2007) 33-36
45. Uszynski W., Uszynski M., and Zekanowska E. Thrombin activatable fibrinolysis inhibitor (TAFI) in human amniotic fluid. A preliminary study. Thromb Res 119 (2007) 241-245
46. Antovic J.P., Rafik Hamad R., Antovic A., Blomback M., and Bremme K. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?. Thromb Haemost 88 (2002) 644-647
47. Alacacioglu I., Ozcan M.A., Alacacioglu A., Polat M., Yuksel F., Demirkan F., et al. Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women. Thromb Res 114 (2004) 155-159
48. De Maat M.P., Jansen M.W., Hille E.T., Vos H.L., Bloemenkamp K.W., Buitendijk S., et al. Preeclampsia and its interaction with common variants in thrombophilia genes. J Thromb Haemost 2 (2004) 1588-1593
49. Boffa M.B., Hamill J.D., Maret D., Brown D., Scott M.L., Nesheim M.E., et al. Acute phase mediators modulate thrombin-activable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells. J Biol Chem 278 (2003) 9250-9257